Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 01

725P - Treatment of patients with metastatic or relapsed cervical cancer: Results from a quality assurance program of the AGO Study Group

Date

14 Sep 2024

Session

Poster session 01

Topics

Therapy

Tumour Site

Cervical Cancer

Presenters

Dominik Denschlag

Citation

Annals of Oncology (2024) 35 (suppl_2): S544-S595. 10.1016/annonc/annonc1592

Authors

D. Denschlag1, F. Heitz2, L.C. Fangmann3, M. Kerkmann4, P.H. Klecker5, L. Woelber6, P. Mach7, A. Fink8, D. Bokhua9, N. de Gregorio10, F. Hemptenmacher11, V. Friebe12, P. Wimberger13, A. Jaeger6, S. Mittelstadt14, M. Kalder15, W. Schröder16, H. Bronger17, P. Harter18, B. Czogalla19

Author affiliations

  • 1 Gynecology, HTK, 65719 - Bad Homburg/DE
  • 2 Gynecology Department, KEM | Evang. Kliniken Essen-Mitte gGmbH, 45136 - Essen/DE
  • 3 Gynecology, Hannover Medical School, 30625 - Hannover/DE
  • 4 Healthcare Research Department, MMF Münster, 48155 - Münster/DE
  • 5 Gynecology, Johannes-Gutenberg Universität Mainz, 55131 - Mainz/DE
  • 6 Gynecology Department, University Medical Center Hamburg-Eppendorf, 20246 - Hamburg/DE
  • 7 Gyncology, University Hospital Essen Westdeutsches Tumorzentrum, 45147 - Essen/DE
  • 8 Gynecological Department, Klinik für Frauenheilkunde und Geburtshilfe (Frauenklinik) - Universitätsklinikum Ulm, 89081 - Ulm/DE
  • 9 Gynecology, Universitätsklinikum Jena, 07743 - Jena/DE
  • 10 Gyncology, SLK-Kliniken Heilbronn GmbH, 74078 - Heilbronn/DE
  • 11 Gynecology, Universitätsklinkum Schleswig-Holstein Campus Lübeck, 23538 - Lübeck/DE
  • 12 Gyncology, UKD - Universitätsklinikum Düsseldorf, 40225 - Düsseldorf/DE
  • 13 Department Of Gynecology And Obstetrics, Universitaetsklinikum Carl Gustav Carus Dresden, 01307 - Dresden/DE
  • 14 Gyncology, Diakonie Klinikum Schwäbisch Hall, 74523 - Schwäbisch Hall/DE
  • 15 Gyncology, UKGM - Uniklinikum Giessen und Marburg - Standort Marburg, 35043 - Marburg/DE
  • 16 Gyncology, Gynaekologicum Bremen, 28209 - Bremen/DE
  • 17 Ob/gyn Dept., TUM - Technical University of Munich, 80333 - Munich/DE
  • 18 Gynecology & Gynecologic Oncology Department, KEM | Evang. Kliniken Essen-Mitte gGmbH, 45136 - Essen/DE
  • 19 Department Of Obstetrics And Gynecology, LMU University Hospital, Munich/DE

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 725P

Background

Real-world data on treatment patterns and outcomes in recurrent or metastatic cervical cancer (r/mCC) are lacking. Hence, understanding treatment patterns and their respective outcome is imperative to design future clinical trials and develop appropriate treatment algorithms.

Methods

Within this retrospective analysis patients with r/mCC diagnosed between 2018 and 2022 were identified from medical records of 31 gynecologic cancer centers in Germany. Patient demographic and clinical characteristics, treatment patterns, and clinical outcomes were assessed descriptively. Progression-free- (PFS) and overall survival (OS) was calculated using Kaplan-Meier analysis.

Results

A total of 503 eligible patients (median age 55 years; IQR 45-63) were analyzed. Thereof 217 (43%) had primary disseminated metastatic disease, and 286 (57%) had recurrent disease, and received systemic treatment for r/mCC. 276/503 patients (55%) received first line (1L) chemotherapy (platinum combination: 247/276; 79%) followed by targeted maintenance therapy with Bevacizumab (177/247; 72%), immunotherapy (19/247; 8%), or both combined (50/247; 20%). 111/503 (22%) received chemotherapy only (platinum combination: 64/111; 58%, platinum mono: 35/111; 31%, or platinum-free: 12/111; 11%), and 110/503 (22%) did not receive any systemic treatment. For these subgroups after a median follow-up of 16 months, the PFS was 12 months (95%-CI 11-14), 8.8 months (95%-CI 7.1-11), and 3 months (95%-CI 2.3-4.8), and OS was 25 months (95%-CI 21-31), 17 months (95%-CI 14-22), and 3.6 months (95%-CI 2.8-5.3), respectively. 176/283 (62%) patients who developed progressive disease (PD) were treated with second line (2L) therapy: platinum-based chemotherapy and maintenance (37/176; 21%); chemotherapy only (65/176; 37%), immunotherapy (59/176; 33%); Antibody-Drug-Conjugate (15/176; 9%).

Conclusions

Only half of the patients with r/mCC were treated 1L with platinum-combination therapy including maintenance. Moreover, 22% at initial diagnosis and 38% at PD were not treated with systemic therapy at all. This might reflect poor performance status, patients’ preference, and/or lack of effective therapies especially in 2L treatment.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

AGO Study Group.

Funding

AGO Research Study Group.

Disclosure

D. Denschlag: Financial Interests, Personal, Invited Speaker: AstraZeneca, GSK, MSD, KLS Martin, Intuitive; Financial Interests, Personal, Advisory Board: AstraZeneca, Eisai, GSK, KLS Martin, MSD, PharmaMar, Seagen. F. Heitz: Financial Interests, Personal, Advisory Board: Roche, AstraZeneca, GSK, NovoCure; Financial Interests, Personal, Invited Speaker: AstraZeneca, GSK. M. Kerkmann: Financial Interests, Personal, Full or part-time Employment: MMF GmbH; Financial Interests, Institutional, Research Grant: AstraZeneca, Roche, Amgen, Bristol Myers Squibb, Janssen-Cilag, Pharmacosmos, MSD, Takeda; Non-Financial Interests, Member: Working Group Medical Oncology (AIO) of the German Cancer Society (DKG), Working Group Supportive Care (AGSMO) of the German Cancer Society (DKG), German Cancer Society (DKG). L. Woelber: Financial Interests, Personal, Advisory Board: GSK, Roche, MSD, Eisai, Seagen, AstraZeneca; Financial Interests, Personal, Invited Speaker: Pfizer, Roche, MSD, Seagen, AstraZeneca, Novartis; Financial Interests, Personal, Other, scientific board: Med Update GmbH; Financial Interests, Personal, Other, speaker: Med Publico GmbH; Financial Interests, Institutional, Coordinating PI: Seagen, Medac Oncology; Financial Interests, Institutional, Local PI: MSD, Vaccibody AS, Roche; Non-Financial Interests, Institutional, Product Samples: Roche diagnostics; Non-Financial Interests, Leadership Role, current president: ECSVD; Non-Financial Interests, Leadership Role: AGO study group, AGO commission vulva vagina. N. de Gregorio: Financial Interests, Personal, Advisory Board: AstraZeneca, Roche, Myriad, Novartis, MSD, GSK, Clovis, Gilead; Other, travel expenses: AstraZeneca, Gilead. P. Wimberger: Financial Interests, Personal and Institutional, Research Funding: Amgen, AstraZeneca, MSD, GSK, Novartis, Pfizer, Roche, Clovis, Lilly; Financial Interests, Personal, Advisory Board: Amgen, AstraZeneca, MSD, GSK, Novartis, Pfizer, Roche, Clovis, Teva, Eisai, Lilly, Gilead, Daichii Sankyo; Financial Interests, Personal, Invited Speaker: Amgen, AstraZeneca, MSD, GSK, Novartis, Pfizer, Roche, Clovis, TEVA, Eisai, Lilly, Gilead, Daichii Sankyo. S. Mittelstadt: Financial Interests, Personal, Sponsor/Funding: AstraZeneca. H. Bronger: Financial Interests, Personal, Invited Speaker: GSK, AstraZeneca. P. Harter: Financial Interests, Personal, Advisory Board, Value includes honoraria for lectures: AstraZeneca; Financial Interests, Personal, Advisory Board, includes honoraria for lectures: GSK, Roche, MSD; Financial Interests, Personal, Invited Speaker: Amgen, Stryker, Zailab, Eisai, Daiichi Sankyo; Financial Interests, Personal, Advisory Board: Clovis, ImmunoGen, Novartis, Mersana, Miltenyi, Exscientia; Financial Interests, Personal, Other, IDMC member: Sotio; Financial Interests, Institutional, Trial Chair: AstraZeneca, Roche, GSK, ImmunoGen; Financial Interests, Institutional, Local PI: Genmab; Financial Interests, Institutional, Funding: Seagen, Clovis; Financial Interests, Institutional, Other, Co-investigator: Novartis; Non-Financial Interests, Principal Investigator: AstraZeneca; Other, Travel support for conference: AstraZeneca. B. Czogalla: Financial Interests, Personal, Invited Speaker: AstraZeneca. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.